

REMARKS

Entry of the foregoing, and reconsideration of applicant's application is respectfully requested in light of the following remarks.

Appendix A is attached hereto, indicating the status as of the date of this amendment of all patent claims and of all added claims in accordance with 37 C.F.R. §1.124(b)(2)(ii).

Claim 26 has been amended to recite that the human protein C of the invention differs from human plasma protein C in that the sialic acid residue content is lower and N-acetylgalactosamine residues are present. The claim previously recited that sialic acid residues were removed and N-acetylgalactosamine residues were added. This language was believed to be confusing since the residues are not physically removed or added, but instead the human protein C has a lower content of sialic acid residues and N-acetylgalactosamine residues when the human protein C is produced in adenovirus-transformed host cells in accordance with the invention. Appendix B is also attached and indicates where exemplary support may be found for the claim as amended in accordance with 37 C.F.R. §1.124(b)(2)(iii).

Claim 17 stands rejected under 35 U.S.C. §102(b) as allegedly being anticipated by Bajaj et al. This rejection is now moot in view of the cancellation of this claim. The cancellation of this claim is made without prejudice or disclaimer of the subject matter set forth therein. Applicants reserve the right to file a continuation application directed to the subject matter of claim 17 at a later time. In view of the above, the rejection of claim 17 is now moot.

Accordingly, the remaining pending claims, claims 1-16 and 18-34 are in condition for allowance. It is noted that the Office Action summary lists claims 1-35. However, in the substitute specification, an error in claim numbering was corrected so that the pending claims were claims 1-34.

Applicant notes the objections to the drawings in the Notice of Draftsperson's Patent Drawing Review. Submitted herewith are the original drawings believed to overcome the Draftsperson's objections.

Further and favorable action in the form of a notice of allowance is respectfully requested. Such action is believed to be in order.

In the event that there are any questions relating to the response or the application in general, it is respectfully requested that the Examiner contact the undersigned attorney by telephone so that prosecution will be expedited. Also, all future correspondence should be directed to the undersigned who is already an attorney of record in this case.

Respectfully submitted,



Brian P. Barrett
Attorney for Applicants
Registration No. 39,597
Phone: 317-276-7243

Eli Lilly and Company
Patent Division/BPB
Lilly Corporate Center
Indianapolis, Indiana 46285

September 21, 2000